Cuál es el precio por Intercept Pharmaceuticals, Inc. (ICPT)

Precio por Intercept Pharmaceuticals, Inc. (ICPT) es de$19.00

Cuál es la capitalización de mercado por Intercept Pharmaceuticals, Inc. (ICPT)

Capitalización de mercado por Intercept Pharmaceuticals, Inc. (ICPT) es $629.64M

Intercept Pharmaceuticals, Inc. (ICPT) Acciones en Circulación

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.

Año	Acciones en circulación	Cambiar
Not enough data for the provided dates.

Año

Acciones en circulación

Cambiar

Not enough data for the provided dates.

Empresa	Acciones en circulación	Diferencia	País
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	478.91M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Empresa

Acciones en circulación

Diferencia

País